Objective: Coagulation factor V (FV) is distributed in plasma and platelet pools, which are distinguished by physical and functional differences. FV has been extensively studied for its roles in coagulation. The roles of FV in other physiologic pathways remain understudied. Methods: Hind limb ischemia was produced in transgenic mice by femoral artery ligation, with different levels of FV gene expression restricted to the plasma or platelets. Results: Hind limb blood flow perfusion in mice with higher platelet FV was significantly increased. The expression of major angiogenesis-related factors was correlated with the level of FV during ischemia. Furthermore, a platelet depletion and transfusion procedure showed that the transfusion of platelets with higher levels of FV into transgenic mice with undetectable platelet FV significantly rescued the ischemia-mediated impairments in blood flow perfusion. Immunohistochemistry analysis also indicated markedly increased capillary formation in the ischemic muscle of mice with higher platelet FV. Moreover, thrombin activity was significantly higher in the mice with higher platelet FV. Platelets expressing higher levels of FV stimulated increased endothelial cell migration. Hind limb blood flow perfusion was significantly blocked by thrombin inhibitor. Conclusions: These findings suggest that platelet-derived FV contributes to the control of angiogenesis and is likely associated with thrombin generation. (J Vasc Surg 2017;65:1180-8.) Clinical Relevance: Platelets and the fibrinolytic system contain many regulators of angiogenesis. Studying the specific roles of individual hemostatic proteins in angiogenesis could lead to novel therapeutic approaches by targeting the angiogenesis functions of the hemostatic proteins. However, the roles of factor V (FV) in angiogenesis have not been reported. This study suggests that platelet-derived FV has an important role in angiogenesis. The stimulation could be partially associated with thrombin generation due to platelet-derived FV.
Factor V (FV) is a central regulatory protein in the blood coagulation cascade that plays critical roles in both procoagulant and anticoagulant pathways. It serves as a critical cofactor for factor Xa, forming the prothrombinase complex to convert prothrombin to thrombin in the presence of calcium and a phospholipid surface. FV is distributed into distinct plasma and platelet compartments, with w80% of total blood FV in the former and w20% in the latter. Clinical and experimental evidence also suggest that human platelet and plasma FV may be functionally distinct.
1,2 Platelet-derived FVa has been reported to be more resistant to activated protein C cleavage and expresses significantly more FXa cofactor activity than plasmaderived FVa. 1 Patients with undetectable plasma FV, but detectable platelet FV, had only relatively mild bleeding, suggesting that platelet FV is critical for coagulation and thrombin generation. 3 Although FV is a critical factor in hemostasis, it can also affect the host's susceptibility to infection due to its effect on thrombin generation. 4 Thrombin is a multifunctional protein that has roles in coagulation as well as in cell proliferation and angiogenesis. Thrombin is a potent activator of angiogenesis, which is independent of its function in fibrin formation. 5 Previous studies demonstrated that thrombin activated angiogenesis through regulation of multiple pathways, such as regulation of vascular endothelial growth factor (VEGF) avb3 integrin, reactive oxygen species, and the expression of the hypoxia inducible factor 1 signaling pathways. [6] [7] [8] Other coagulation factors, such as tissue factor and factor X are also involved in controlling angiogenesis. 9, 10 Platelets and the fibrinolytic system contain many regulators of angiogenesis. 11, 12 Studying the specific roles of individual hemostatic proteins in angiogenesis could lead to novel therapeutic approaches to treat cancers and ischemia by targeting the angiogenesis functions of the hemostatic proteins. However, no studies have implicated FV in controlling angiogenesis. Given that platelet FV affects thrombin generation, we hypothesized that platelet FV could play an important role in angiogenesis.
METHODS
The protocols for animal use in this study were reviewed and approved by the Animal Care Committee of Sichuan Medical University in accordance with the Institutional Animal Care and Use Committee guidelines.
Animals.
À/À mice were previously generated and characterized 13 on a background strain of C57BL/6 mice. The mice exhibited different levels of FV gene expression restricted to the plasma or platelets (Tg Immunoblotting. Isolated mouse platelets were homogenized in radioimmunoprecipitation assay buffer (Sigma-Aldrich, St. Louis, Mo). Equal amounts of protein underwent sodium dodecyl sulfate-polyacrylamide gel electrophoresis and were transferred to polyvinylidene difluoride membranes by electroblotting. After blocking, the membranes were incubated with anti-FV antibody (a gift from Dr David Ginsburg, University of Michigan) and b-actin.
Mouse hind limb ischemia model. Unilateral hind limb ischemia was induced in mice by ligation and excision of a segment of the left femoral artery, as previously described. 14, 15 Mice were anesthetized using intraperitoneal sodium pentobarbital (60 mg/kg body weight) or isoflurane (5% by inhalation). A subcutaneous dose of buprenorphine hydrochloride (0.1 mg/kg) was administered for analgesia. Additional sodium pentobarbital (12 mg/kg body weight) or 5% isoflurane was given as needed to maintain anesthesia.
The proximal portion of the femoral artery and the distal portion of the saphenous artery were ligated, and excision of the femoral bifurcation with all branches was performed. To minimize ambient light and temperature variation, mice were kept on a heating plate at 37 C for w10 minutes before measurement in a darkened room. 14 Perfusion of the ischemic and nonischemic hind limb of the distal foot was measured in each mouse by laser Doppler imaging immediately before surgery, immediately after ligation, and at 3, 7, 12, and 14 days after ligation using a scanning moorLDI2-HIR (Moor Instruments, Wilmington, Del) high-resolution laser Doppler imager.
Quantitative real-time polymerase chain reaction. The ischemic gastrocnemius muscle was excised, embedded in paraffin, and cross-sections were prepared for immunofluorescence analysis. Total RNA was extracted from the ischemic gastrocnemius muscles using TRIzol (Invitrogen, Carlsbad, Calif). RNA was pretreated with DNA (Invitrogen Life Technologies, Grand Island, NY), and SuperScript (Invitrogen Life Technologies) was used to synthesize complementary DNA according the manufacturer's recommended conditions. Each sample was analyzed in duplicate with ribosomal 18S messenger RNA used as a control. After amplification, the relative differences in the amount of RNA were calculated based on the 2 ÀDDCT method. The oligonucleotide sequences of the polymerase chain reaction primers were:
(1) VEGF-A (GCAGGCTGCTGTAACGATGAA, TCACATCTGCTGTGCTGTAGGA); (2) fibroblast growth factor (FGF)-2 (GGACG GCTGCTGGCTTCTAA, CCAGTTCGTTTCA GTGCCACATAC); (3) monocyte chemoattractant protein (MCP)-1 (CAGCCAGATGCAGTTAACGC, GCCTACT-CATTGGGATCATCTTG); and (4) 18S (CCTGGATACCGCAGCTAGGA, GCGG CGCAATACGAATGCCCC).
Thrombin activity assay. Blood was collected into citrate anticoagulant tubes, and plasma was prepared by centrifugation. The ischemic muscles were homogenized with 0.3 mL of phosphate-buffered saline (pH 7.2), and the homogenates were centrifuged at 12,000g for 15 minutes. Thrombin activity was measured using a SensoLyte 520 Thrombin Assay Kit (AnaSpec Inc, Fremont, Calif).
Platelet depletion. To deplete endogenous platelets, mice were injected intraperitoneally every 3 days with 2.5 mg/g mouse platelet-depleting antibody (polyclonal anti-mouse glycoprotein Ib-a rat immunoglobulin G [IgG]; Emfret Analytics, Eibelstadt, Germany), and the platelets were counted.
Platelet isolation and transfusion. To determine whether platelet-derived FV contributes to microvascular angiogenesis during rodent hind limb ischemia, mice were anesthetized, as described above, and whole blood was collected from the inferior vena cava using a 1 mL syringe containing 0.1 mL sodium citrate anticoagulant. Plateletrich plasma (PRP) was obtained from whole blood by centrifugation at 260g for 8 minutes and 260g for an additional 3 minutes. The supernatant was collected after each centrifugation. The platelets were isolated from the PRP using a Sepharose 2B column in PIPES buffer (PIPES, 5 mM; NaCl, 1.37 mM; KCl 4, mM, glucose 0.1%, pH 7.0).
Platelet-poor plasma (PPP) was prepared by centrifugation at 1500g for 20 minutes. The PPP was further centrifuged at 10,000g for 5 minutes to remove the remaining cells. The pellet containing the platelets was then resuspended in 1 mL of phosphate-buffered saline (SigmaAldrich), allowed to sit for 30 minutes, and the platelets were counted with a hemocytometer. The platelets from the suspension were diluted with normal saline to a concentration of 1.56 Â 10 9 platelets in 1.2 mL. We transfused 0.2 mL of the suspension via the tail vein into each recipient mouse every 6 days.
Injection of hirudin. We injected a subset of Tg
mice subcutaneously with hirudin (1.5 mg/kg body weight; Perfemiker, Shanghai, China) or saline once daily starting day 1 after surgery until 14 days. Perfusion of the ischemic and nonischemic hind limb was measured in each mouse.
Immunofluorescence. Middle sections of the isolated ischemic gastrocnemius muscle were fixed in 4% paraformaldehyde, embedded in paraffin, and serially cut into 10-mm-thick sections. After the standard histologic procedures, the sections were incubated overnight at 4 C with 1:50 anti-platelet endothelial cell adhesion molecule (PECAM-1) and anti-CD41 antibodies (Santa Cruz Biotechnology Inc, Santa Cruz, Calif). The sections were incubated with 1:100 goat anti-rabbit IgG AlexaFluor 488-conjugated antibody or 1:100 goat anti-mouse IgG AlexaFluor 568-conjugated antibody (both Molecular Probes, Invitrogen). Images were captured using an Olympus (DP70) microscope (Melville, NY) and evaluated using the Photoshop CS4 (Adobe, San Jose, Calif) function.
The capillaries within the gastrocnemius muscle were immunostained with anti-PECAM-1 antibody. The percentage of area positive for PECAM-1 or total number of capillaries around each fiber was determined throughout entire cross-sectional regions. [14] [15] [16] Quantification was performed by analyzing at least three sections and three fields per sample.
Cell migration. Mouse aortic endothelial cell (EC) migration was studied using transwell migration chambers (Life Technologies) with bottom membranes containing 8-mm pores. ECs (2 Â 10 4 ) were added to the upper chamber and treated with hirudin (2 mg/mL) or the vehicle control for 30 minutes, followed by adding purified platelets (3 Â 10
þ Fv À/À mice to the upper chamber. After incubation for 24 hours at 37 C in a humidified chamber with 5% CO 2 , the ECs that migrated to the lower-chamber were stained with 0.5% crystal violet and counted.
Data analysis. Image analyses were performed in a blinded fashion. The data are presented as the mean 6 standard error of the mean. The experimental groups were compared using the two-tailed Student t-test or one-way analysis of variance.
RESULTS
FV promoted recovery of hind limb reperfusion after femoral artery ligation. In previous studies, we generated transgenic mice with different levels of plasma and platelet pools of FV. FV in either pool is sufficient for hemostasis. 13 These mice were generated by crossing tissue-specific FV transgenes into an FV-null background. The transgenic line AlbfvB was used in the current study. 13 The transgene expressed FV from a liver-specific promoter. As a result, the Tg þ
F5
À/À mouse expresses w15% of the wild-type plasma FV level with no detectable level of platelet FV. As demonstrated using Western blot analysis, Tg þ Fv À/À mice had no detectable level of platelet FV and the lowest level of PPP FV (Fig 1) .
To determine whether FV mediates the formation of functional vasculature, hind limb ischemia was induced in 
, and Tg þ Fv À/À mice were analyzed using Western blotting with anti-FV antibody. The graphs correspond to the blots and represent densitometric analyses of three independent experiments. The error bars show the standard error of the mean.
FV transgenic mice by ligation and excision of the femoral artery. Laser Doppler imaging revealed that the blood flow perfusion of the ischemic hind limb tissue after femoral artery interruption was significantly higher in Tg À Fv þ/þ mice than in mice with lower levels of plasma and platelet FV (Tg Fig 2, A and B) . The capillary formation in ischemic muscle was also correlated with the level of FV, in agreement with these results. The capillary density in the ischemic gastrocnemius muscle 2 weeks after induction of ischemia was significantly higher in (Fig 2, C-E) . FV-mediated proangiogenic activity is associated with thrombin generation. Thrombin is a potent angiogenesis activator, and FV could exert its effect on microvascular angiogenesis through thrombin. To study the potential mechanisms by which FV promotes ischemiamediated angiogenesis, thrombin activity was measured in PPP, PRP, or hind limb ischemic muscles. As expected, the level of thrombin activity was highest in Tg À Fv þ/þ mice and was lowest in Tg þ Fv À/À mice (Fig 3, A) . The thrombin activity in the PRP of transgenic mice, with different levels of FV, was significantly greater than that of PPP, indicating the contribution of platelets to thrombin generation. Interestingly, thrombin activity in the PRP of Tg þ Fv À/À mice was much higher than in PPP, suggesting that the presence of platelets, even without platelet FV, could still enhance thrombin generation. However, thrombin activity in ischemic muscles did not differ among (Fig 3, B) , suggesting that thrombin in the general circulation could partially lead to the difference in angiogenesis.
To determine the role of thrombin in the involvement of FV modulation in ischemia-mediated flow perfusion, we used the direct thrombin inhibitor, hirudin, in the Tg À Fv þ/þ mouse hind limb ischemia model. Mice were subcutaneously administered hirudin (1.5 mg/kg body weight) or saline once daily after surgery for 14 days. Laser Doppler imaging revealed that the blood flow perfusion of the ischemic hind limb tissue after femoral artery interruption was significantly blocked at 7, 12, and 14 days in hirudintreated mice compared with vehicle-treated control mice (Fig 3, C and D) . We next examined the effect of FV on plateletmediated endothelial cell migration in vitro. Mouse aortic ECs were coated on wells and then incubated with platelets or PPP derived from Tg 
Fv
À/À mice (Fig 3, E) . We next studied the effects of FV on mouse aortic EC migration in the presence and in Factor V (FV)-mediated proangiogenic activity is associated with thrombin generation. A, Thrombin activity was analyzed in platelet-rich plasma (PRP) and platelet-poor plasma (PPP) using a thrombin activity assay. * P < .05 vs Tg
. B, Thrombin activity was analyzed in ischemic muscles from Tg
respectively. (C) Representative laser-Doppler images of mouse hind limbs at indicated times after femoral artery ligation in Tg

À
Fv
þ/þ mice treated with hirudin. D, Mean ratio of blood flow in ischemic and nonischemic hind limb footpads for all animals (n ¼ 6 per group) at indicated times. * P < .05 hirudin-treated group vs vehicle control. E, Cocultivation of endothelial cells (ECs) and platelets or PPP. ECs were grown on the upper chamber of transwell migration chambers and treated with hirudin or the vehicle control for 30 minutes, followed by the addition of purified platelets or PPP from
After 24 hours at 37 C, the membranes were excised and stained. ECs that migrated to the lower chamber were counted. The means 6 standard error of the mean (range bars) of three independent experiments are shown. * P < .05 vs Tg Messenger RNA expression of major angiogenesis-related factors in ischemic muscles as assessed by real-time polymerase chain reaction. The mRNA expression of (A) vascular endothelial growth factor A (VEGF-A), (B) fibroblast growth factor 2 (FGF-2), and (C) monocyte chemoattractant protein 1 (MCP-1) were analyzed using real-time reverse-transcription polymerase chain reaction in Tg
The data were standardized by the expression level of 18S in each sample and are presented as the expression relative to nonischemia (n ¼ 6 per group). All values represent the mean 6 standard error of the mean (error bars).
JOURNAL OF VASCULAR SURGERY the absence of hirudin. The promigratory effects of platelet-FV were lost in the presence of hirudin (Fig 3, E) . Together, these results supported the functional significance of platelet-derived FV in angiogenesis and its thrombin dependence. FV-mediated angiogenic factors are essential for ischemia-induced angiogenesis. To examine the potential roles of angiogenic factors in mediating blood flow perfusion by FV, we conducted a relative assessment of the gene expression of angiogenesis-related factors and arteriogenic molecules. Quantitative analysis by real-time polymerase chain reaction revealed that VEGF-A, FGF-2, and MCP-1 gene expression were upregulated in the ischemic muscles of Tg À Fv þ/þ mice compared with the lower levels of plasma and platelet FV (Tg
) at 14 days after surgery (Fig 4) . These results may suggest that the expression of angiogenic factors is correlated with the level of FV during ischemia. Platelet FV promotes recovery of hind limb reperfusion. To study the contribution of platelet FV in ischemic reperfusion, we used a platelet depletion and reinfusion model to examine hind limb ischemia-induced angiogenesis in different groups (Tg
. Consistent with our previous report, 17 platelet counts were successfully reduced using anti-mouse glycoprotein Ib-a rat IgG. We also evaluated the effect of platelet depletion on thrombin activity in
and Tg þ Fv À/À mice. Thrombin activity in PRP with different level of FV was significantly greater than that of platelet depletion; however, no difference was found in thrombin activity of PPP between normal the platelet and A, Representative laser-Doppler images at indicated times after femoral artery ligation in mice during the platelet depletion and reinfusion model. B, Mean ratio of blood flow in ischemic and nonischemic hind limb footpads for all animals at indicated times (n ¼ 6 per group). * P < .05, Tg
. C, Representative laser-Doppler images of mouse hind limbs at indicated times during the platelet depletion and reinfusion model from the Tg
Mean ratio of blood flow in ischemic and nonischemic hind limb footpads for all animals at indicated times (n ¼ 6 per group). * P < .05, Tg
À/À at 14 days. E, Representative images of capillaries assessed using anti-platelet endothelial cell adhesion molecule 1 (PECAM-1) immunostaining in ischemic gastrocnemius muscles recovered 2 weeks after femoral artery interruption. Scale bars ¼ 100 mm. F, Mean capillary density in ischemic gastrocnemius muscles assessed using anti-PECAM-1 immunostaining. G, Mean PECAM-1-positive microvessel/muscle fiber ratio in ischemic gastrocnemius muscles (n ¼ 6 per group). The error bars indicate the standard error of the mean. * P < .05 vs Tg
platelet-depletion groups ( Supplementary Fig, online only) , indicating the contribution of platelet to thrombin generation. Reinfusion of platelets from a donor mouse to the thrombocytopenic mice successfully restored platelet counts. The blood flow perfusion level was increased 2.09-fold at 2 weeks in the (Fig 5, A and B) . Similarly, with Tg À Fv þ/þ platelet infusion, the blood flow perfusion level was increased 1.98-fold at 7 days and 1.36-fold at 2 weeks in Tg þ Fv À/À mice (Fig 5, C and D) . Consistent with these results, the capillary density in ischemic gastrocnemius muscles 2 weeks after the induction of ischemia was significantly higher in Tg (Fig 5, E-G) . Thus, the infusion of platelets with higher levels of FV promoted blood flow recovery after surgery.
To test whether the proangiogenic effect of plateletderived FV is associated with the deposition of platelets, we further examined the deposition of platelets by assessing anti-CD41 immunostaining in the ischemic gastrocnemius muscles recovered 2 weeks after surgery. Fig 6, A and B) . Similarly, the number of extracapillary platelets in ischemic gastrocnemius muscles 2 weeks after the induction of ischemia was significantly higher in Tg Fig 6,  C and D) . These data suggested that the platelets with higher levels of FV were more likely to be aggregated and activated at injury sites.
DISCUSSION
In our previous studies, we generated mice with different levels of FV in the plasma and platelet pools, leading to changes in thrombin generation. Interestingly, these mice demonstrated different susceptibilities to bacterial infection, which could be partially attributed to differences in thrombin generation. 4 These mice thus can also be used to explore the effect of FV in angiogenesis. We used a hind limb reperfusion model after femoral artery ligation to study angiogenesis. We previously used this model to study how plasminogen activator inhibitor-1 affected angiogenesis. 18 Femoral artery ligation was performed in three groups of mice that had different levels of FV in their plasma and platelet pools. Significantly reduced reperfusion rates were observed in mice with lower FV levels (Fig 2, A) , suggesting reduced angiogenesis, which was supported by lower levels of capillary density as represented by Fig 6 . Deposition of platelets in ischemic muscles after femoral artery ligation. A, Representative images of capillaries and platelets assessed using anti-platelet endothelial cell adhesion molecule 1 (PECAM-1; red color) and CD41 (green color) immunostaining in ischemic gastrocnemius muscles recovered 2 weeks after femoral artery interruption, respectively. Scale bars ¼ 100 mm. B, Mean platelet density in ischemic gastrocnemius muscles assessed using anti-CD41 immunostaining (n ¼ 6 per group). * P < .05 vs Tg
. C, Representative images of capillaries and platelets in ischemic gastrocnemius muscles. D, Mean platelet density in ischemic gastrocnemius muscles assessed using anti-CD41 immunostaining (n ¼ 6 per group). A and C, The arrow indicates CD41-positive platelets; the arrowhead indicates merged anti-PECAM-1 and CD41-positive cells. The error bars indicate the standard error of the mean. * P < .05 vs Tg
PECAM-1 levels (Fig 2, B) . The expression of angiogenesis-related genes (VEGF-A and FGF-2), as well as MCP-1, were correlated with the level of FV during ischemia. The level of angiogenesis also correlates with FV levels.
In our previous studies, we demonstrated that the prothrombin time in Tg þ Fv À/À mice was significantly increased, suggesting defects in thrombin generation. 13 As expected, thrombin activity in the PPP and PRP of mice with different levels of FV were closely correlated with their FV levels. Tg þ Fv À/À mice had the lowest thrombin activity in both PPP and PRP and also had the lowest level of angiogenesis. Furthermore, thrombin inhibitors blocked perfusion in Tg À Fv þ/þ mice, indicating that FV mediated flow perfusion due to thrombin generation. Using an in vitro EC migration assay, we also found that platelets with higher levels of FV demonstrated stronger promigratory effects, which were abrogated by thrombin inhibitors, strongly supporting the proangiogenesis role of platelet FV.
These results further supported the hypothesis that lower levels of FV could lead to lower thrombin generation and thus lead to a lower level of angiogenesis, although multiple factors could be involved. To further dissect the contribution of plasma and platelet FV to angiogenesis, mice with lower levels of FV were infused with platelets with higher levels of FV, leading to increased reperfusion rates and capillary density. These results suggested that increase platelet FV levels could significantly increase angiogenesis. Platelets with higher FV were also observed to aggregate at injury sites, which was directly correlated with higher ischemia-mediated capillary formation. Platelet activation simultaneously releases multiple proangiogenic and antiangiogenic regulators. 19 Our data demonstrated that platelet FV is one of the proangiogenesis regulators and could be one of the important factors participating in capillary network formation enhanced by platelet release.
A limitation of our hind limb ischemia model experiment is that we cannot definitively conclude that the angiogenic effects of platelet-derived FV are due to thrombin generation. Nevertheless, our hind limb ischemia model data support the significance of our proposed molecular mechanisms in a clinically relevant in vivo context, which demonstrated that FV promotes ischemia-mediated angiogenesis. Additional in vivo studies will be necessary to further dissect and better characterize the mechanisms, such as recombinant FV protein infusion, assessment of arteriogenesis, overexpression of thrombin, inflammatory cell infiltration studies, and so on.
CONCLUSIONS
A new platelet-dependent pathway for angiogenesis that does not significantly affect hemostatic balance could serve as a potential angiogenic therapeutic target. Our finding of the effect of platelet FV in angiogenesis could open another venue for modulating angiogenesis for therapeutic benefits. Of note, targeting thrombin and the coagulation system could lead to severe adverse effects, such as excessive clotting or bleeding. However, targeting only platelet FV could significantly diminish bleeding risks, because plasma FV could still provide sufficient coagulation activity.
